Summary
Marga Ortigas-Wedekind, a director of HeartBeam, Inc. (NASDAQ:BEAT), reported a personal purchase of 25,000 common shares on April 16, 2026. At $0.80 per share, the trade totaled $20,000 and increased her direct ownership in the company to 137,293 shares. The transaction was completed in connection with an underwritten public offering that the company priced on April 14, 2026 and closed on April 16, 2026.
Transaction details
Ortigas-Wedekind’s acquisition was executed at $0.80 per share for a total outlay of $20,000. Following the purchase, she holds 137,293 shares directly. The market price at the time of reporting was $0.81, and the stock is reported to be down 66% year-to-date. An InvestingPro analysis cited alongside the transaction notes that the stock appears undervalued at current levels.
Offering and bookrunning
The insider purchase was linked to HeartBeam’s underwritten public offering of 12,500,000 shares of common stock. Titan Partners, a division of American Capital Partners, served as the sole bookrunner for that offering. The offering was priced on April 14, 2026 and closed on April 16, 2026.
Company financing and structure
HeartBeam announced the closing of a $10 million public offering in which it sold 12.5 million shares of common stock at $0.80 per share. The company granted the underwriters a 30-day option to purchase an additional 1.875 million shares to cover any over-allotments. ClearCardio participated in leading the offering alongside HeartBeam’s executive leadership and institutional investors.
Analyst coverage and product notes
Recent analyst activity includes coverage initiations by two firms. B. Riley started coverage with a Buy rating and set a price target of $4.00, while D. Boral Capital initiated coverage with a Buy rating and a $5.00 price target. Both firms highlighted aspects of HeartBeam’s technology: an FDA-cleared device that can synthesize a clinical-grade 12-lead ECG, and ambulatory electrocardiogram technology intended for continuous cardiac monitoring.
Research resources
For investors seeking deeper financial analysis, a comprehensive Pro Research Report is available for HeartBeam along with coverage on more than 1,400 other U.S. equities, according to the materials associated with the company’s filings and coverage notes.
Key points
- Director Marga Ortigas-Wedekind bought 25,000 HeartBeam shares on April 16, 2026 at $0.80 per share, totaling $20,000, increasing her direct stake to 137,293 shares.
- The purchase was tied to an underwritten public offering of 12,500,000 shares that priced on April 14, 2026 and closed April 16, 2026, with Titan Partners acting as sole bookrunner.
- HeartBeam closed a $10 million offering at $0.80 per share and granted underwriters a 30-day option for up to 1.875 million additional shares; ClearCardio joined company leadership and institutional investors in the offering.
Sectors impacted
- Healthcare - medical device and cardiac monitoring technology.
- Capital markets - equity financing and analyst coverage dynamics.
Risks and uncertainties
- Share-price volatility - the stock is trading at $0.81 and is down 66% year-to-date, reflecting high near-term price variability that could affect investors in the healthcare and small-cap equities sectors.
- Financing dilution risk - the public offering and the underwriters’ 30-day option to purchase additional shares create potential dilution for existing shareholders in the near term.
- Coverage interpretation - analyst initiation with Buy ratings and price targets does not guarantee results and introduces differing assessments that investors must weigh when considering exposure to medical device equities.
Note: All transaction and offering specifics reflect company reporting and filings for the dates and terms stated above.